Contract facts
UnrestrictedNo full NAICS 325412 intel page yet. Browse NAICS intelligence
TRANSARTERIAL RADIOEMBOLIZATION USING YTTRIUM-90 MICROSPHERES IS A THERAPEUTIC OPTION FOR PATIENTS WITH INTERMEDIATE-OR ADVANCED-STAGE HEPATOCELLULAR CARCINOMA, INCLUDING THOSE WITH RECURRENT OR INOPERABLE HEPATOCELLULAR CARCINOMA. is a federal Unrestricted award for W40m Mrc0 West held by Boston Scientific Corp. Estimated value $553K ($553K obligated). Current period of performance ends Sep 30, 2026. Last award drew 1 bidder. Place of performance: JBSA FT SAM HOUSTON TX.
TRANSARTERIAL RADIOEMBOLIZATION USING YTTRIUM-90 MICROSPHERES IS A THERAPEUTIC OPTION FOR PATIENTS WITH INTERMEDIATE-OR ADVANCED-STAGE HEPATOCELLULAR CARCINOMA, INCLUDING THOSE WITH RECURRENT OR INOPERABLE HEPATOCELLULAR CARCINOMA.
Recompete timing
PublicCurrent PoP ended Sep 30, 2026 (1 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Want the durability read on W81K0025PA252? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordBoston Scientific Corp — $69.8M obligated across 5,464 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).
Related awards
Same incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract W81K0025PA252?
W81K0025PA252 (Transarterial radioembolization USING) is a W40m Mrc0 West award with a potential value of $553K, currently held by Boston Scientific Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded W81K0025PA252?
W40m Mrc0 West awarded W81K0025PA252 to Boston Scientific Corp (potential $553K).
Who is the incumbent on W81K0025PA252?
Boston Scientific Corp is the incumbent with $69.8M across 5464 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2026.
When does Boston Scientific Corp’s W81K0025PA252 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 30, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on W81K0025PA252? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Buy one Pursuit Analysis — $500Credits toward the Sprint Pack
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.